BPTS — Biophytis SA Share Price
Last trade - 00:00- $16.19m
- $5.88m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.1 | ||
| PEG Ratio (f) | 0 | ||
| EPS Growth (f) | 143.28% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.68 | ||
| Price to Tang. Book | 5.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -204.4% | ||
| Return on Equity | -777.65% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | n/a | 159 | 109 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | -32.74 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
Directors
- Stanislas Veillet CHM (56)
- Evelyne Nguyen FID (52)
- Pierre Dilda CSO
- Rene Lafont CSO (75)
- Waly Dioh OTH
- Rob Maanen OTH
- Benoit Canolle EXB
- Claude Allary DRC
- Dimitri Batsis DRC (56)
- Nadine Coulm DRC
- Marie-Claire Janailhac-Fritsch DRC (66)
- Last Annual
- December 31st, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- April 20th, 2007
- Public Since
- July 13th, 2015
- No. of Employees
- 22
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 135,953,657
- Address
- 14 avenue de l'Opera, PARIS, 75001
- Web
- http://www.biophytis.com/
- Phone
- +33 141836600
- Auditors
- Ernst & Young et Autres
Similar to BPTS
180 Life Sciences
NASDAQ Capital Market
9 Meters Biopharma
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acer Therapeutics
NASDAQ Capital Market
FAQ
As of Today at 13:03 UTC, shares in Biophytis SA are trading at $1.00. This share price information is delayed by 15 minutes.
Shares in Biophytis SA last closed at $1.00 and the price had moved by -90.57% over the past 365 days. In terms of relative price strength the Biophytis SA share price has underperformed the S&P500 Index by -89.15% over the past year.
The overall consensus recommendation for Biophytis SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Biophytis SA does not currently pay a dividend.
Biophytis SA does not currently pay a dividend.
Biophytis SA does not currently pay a dividend.
To buy shares in Biophytis SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.00, shares in Biophytis SA had a market capitalisation of $16.19m.
Here are the trading details for Biophytis SA:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BPTS
Based on an overall assessment of its quality, value and momentum Biophytis SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biophytis SA is $12.61. That is 1161.08% above the last closing price of $1.00.
Analysts covering Biophytis SA currently have a consensus Earnings Per Share (EPS) forecast of €11.30 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biophytis SA. Over the past six months, its share price has underperformed the S&P500 Index by -74.87%.
As of the last closing price of $1.00, shares in Biophytis SA were trading -82.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biophytis SA PE ratio based on its reported earnings over the past 12 months is 0.1. The shares last closed at $1.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biophytis SA's management team is headed by:
- Stanislas Veillet - CHM
- Evelyne Nguyen - FID
- Pierre Dilda - CSO
- Rene Lafont - CSO
- Waly Dioh - OTH
- Rob Maanen - OTH
- Benoit Canolle - EXB
- Claude Allary - DRC
- Dimitri Batsis - DRC
- Nadine Coulm - DRC
- Marie-Claire Janailhac-Fritsch - DRC